- Report
- January 2022
- 60 Pages
Global
From €3753EUR$3,950USD£3,218GBP
- Report
- January 2022
- 200 Pages
Global
From €7125EUR$7,500USD£6,110GBP
- Report
- January 2022
- 200 Pages
Global
From €7125EUR$7,500USD£6,110GBP
- Report
- May 2020
- 100 Pages
Global
From €2708EUR$2,850USD£2,322GBP
- Report
- October 2023
- 82 Pages
United Kingdom
From €3325EUR$3,500USD£2,851GBP
- Report
- April 2023
- 116 Pages
Global
From €4655EUR$4,900USD£3,992GBP
- Report
- September 2021
- 40 Pages
China
From €2470EUR$2,600USD£2,118GBP
- Report
- September 2021
- 40 Pages
China
From €2470EUR$2,600USD£2,118GBP
- Report
- July 2021
- 50 Pages
China
From €2470EUR$2,600USD£2,118GBP
From €2470EUR$2,600USD£2,118GBP
- Report
- June 2021
- 50 Pages
China
From €2470EUR$2,600USD£2,118GBP
- Report
- May 2021
- 50 Pages
China
From €2470EUR$2,600USD£2,118GBP
- Report
- April 2021
- 50 Pages
China
From €2470EUR$2,600USD£2,118GBP
- Report
- August 2019
- 30 Pages
China
From €2090EUR$2,200USD£1,792GBP
- Report
- July 2023
- 127 Pages
Australia
From €1995EUR$2,100USD£1,711GBP
€2850EUR$3,000USD£2,444GBP
- Report
- November 2020
- 49 Pages
Global
€1252EUR$1,318USD£1,074GBP
- Drug Pipelines
- September 2019
- 114 Pages
Global
€9500EUR$10,000USD£8,146GBP
- Drug Pipelines
- September 2019
- 118 Pages
Global
€9500EUR$10,000USD£8,146GBP
- Drug Pipelines
- September 2019
- 65 Pages
Global
€9500EUR$10,000USD£8,146GBP
- Drug Pipelines
- March 2019
- 111 Pages
Global
€9500EUR$10,000USD£8,146GBP
The Lung Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat lung cancer. These drugs are used to treat both non-small cell and small cell lung cancer, the two most common types of lung cancer. The drugs are designed to target the cancer cells and stop them from growing and spreading. Common treatments include chemotherapy, targeted therapy, immunotherapy, and radiation therapy.
The Lung Cancer Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Companies such as Bristol-Myers Squibb, Merck, Pfizer, AstraZeneca, and Roche are all major players in the market. These companies are constantly researching and developing new drugs to treat lung cancer, as well as improving existing treatments.
In addition, there are many smaller companies that specialize in the development of new drugs for the treatment of lung cancer. These companies often collaborate with larger pharmaceutical companies to bring their drugs to market. Examples of these companies include ImmunoGen, Inc., Oncolytics Biotech, and ImmunoCellular Therapeutics. Show Less Read more